1Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[ J]. N Engl J Med, 2009, 361 ( 11 ): 1045-1057. DOI: 10. 1056/ NEJMou0904327.
2Harem CW,Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [ J ]. Eur Heart J, 2011 , 32 ( 23 ) : 2999-3054. DOI : 10.1093/eurheartj/ebr236.
3O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infaretion: a repart of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[ J]. J Am Coll Cardiol,2013,61 (4) :e78-e140. DOI: 10. 1016/j. jacc. 2012.11. 019.
4Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) [J]. Eur Heart J,2014,35(37) :2541-2619. DOI:10. 1093/eurheartj/ehu278.
5Amsterdam EA,Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[ J ]. Circulation, 2014,130 ( 25 ) : e344-e426. DOI : 10. 1161/CIR. 0000000000000134,.
6Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCBI single nucleotide polymorphisms on outcomes of treatment with tieagrelor versus clopidogrel for acute coronary syndromes:a genetic substndy of the PLATO trial [ J ]. Lancet, 2010. 376 (9749) : 1320-1328. DO1 : 10. 1016/S0140-6736 ( 10) 61274-3.
7Li H, Butler K,Yang L, et al. Pharmacokinetics and tolerability of single and multiple doses of tieagrelor in healthy Chinese subjects : an open-label, sequential, two-cohort, single-centre study [ J]. Clin Drug Investig, 2012, 32 ( 2 ) : 87-97. DOI: 10. 2165/ 11595930.-000000000-00000.
9Bliden KP, Tantry US, Storey RF, et al. The eftect of ticagrelor versus clopidogrel on high on-treatment platelel reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies [ J ]. Am Heart J,2011,162 ( 1 ) : 160-165. DOI : 10. 1016/j. ahj. 2010. 11.0:25.
10Storey RF, Angiolillo D J, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes:the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy [J ]. J Am Coll Cardiol,2010,56( 18 ) :1456-1462. DOI: 10. 1016/j. jacc. 2010. 03. 100.
